What is Indegene Ltd (INDGN) share price return in the past 10 years?

Data is not available for this company

What is the share price of Indegene Ltd (INDGN)?

Company share prices are keep on changing according to the market conditions. The current trading price of Indegene Ltd (INDGN) on 11-Jun-2026 15:07:00 at 15:07 is 505.45.

What is the P/E ratio of Indegene?

The latest standalone P/E ratio of Indegene as of 11-Jun-2026 is 58.95.

What is the P/B ratio of Indegene Ltd (INDGN)?

The latest standalone P/B ratio of Indegene Ltd (INDGN) as of 11-Jun-2026 is 6.00.

What is the 52-week high and low of Indegene Ltd (INDGN)?

The 52-week high of Indegene Ltd (INDGN) is Rs. 620.00 and the 52-week low is Rs. 414.90.

Indegene Ltd (INDGN) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Indegene Ltd (INDGN)
Brand: Indegene

Key Metrics

Valuation Multiples

Market Cap

₹12,492 Cr.

Current Price

₹505.5

52-Week Low / High

₹415 / 620

TTM EPS

₹16.7

TTM Sales

₹3,511 Cr.

Book Value per Share

₹130.3

P/E Ratio

31.14

Higher than its 5-year historical median

Industry PE

22.9

Price to Book (P/B)

3.98

In line with its 5-year historical median

Price to Sales (P/S)

3.56

Lower than its 5-year historical median

EV/EBITDA

17.53

In line with its 5-year historical median

Dividend Yield

0.35%

Profitability Efficiency

Return on Equity (ROE)

20.45%

Outperforms industry median

Return on Capital Employed (ROCE)

25.24%

Outperforms industry median

Return on Assets (ROA)

14.24%

Operating Profit Margin

18.8%

Net Profit Margin

14.32%

Gross Profit Margin

21.8%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

9.64%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

5.72%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

20.79%

Asset Quality

Promoter Holding

0.00%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹3,091 Cr.

Equity

₹48.2 Cr.

Face Value

₹2

All Time Low / High

₹414.90 / 736.60

Indegene stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Indegene Ltd a good quality company?

Indegene Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Indegene Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Indegene Ltd vs industry peers?

Indegene Ltd revenue CAGR is 34.59%, compared to the industry median CAGR of 0.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Indegene Ltd?

Promoters hold 0.00% of the Indegene Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Indegene Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of -15.7% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	43.7%	33.3%	8.9%	14.8%	29.7%	68.5%	41.1%	35.2%	30.9%	25.2%	-
Value Creation Index ⓘ	2.2	1.5	-0.3	0.1	1.2	4.1	2.0	1.5	1.2	0.9	-
Growth Parameters ⓘ
Sales ⓘ	344	472	475	553	643	966	1,665	2,306	2,590	2,839	3,511
Sales YoY Gr.	-	37.3%	0.7%	16.5%	16.2%	50.3%	72.3%	38.5%	12.3%	9.6%	-
Adj EPS ⓘ	1.7	2	0.2	0.5	4.3	9.1	8.2	10.8	14.6	16.7	16.7
YoY Gr.	-	17.1%	-92.5%	253.3%	713.2%	110.7%	-9.9%	31.5%	35.5%	14.5%	-
BVPS (₹) ⓘ	0.6	2.6	2.8	3.6	-5.6	16.2	34.3	47.2	63	107.7	130.3
Adj Net Profit ⓘ	33.1	39.1	3	10.6	85.1	179	181	238	324	400	401
Cash Flow from Ops. ⓘ	28.8	27.5	23.6	64.6	22.4	172	297	130	508	442	-
Debt/CF from Ops. ⓘ	0.5	2.8	3.2	1.1	20.1	0.1	0.1	3	0.8	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26.4%	34.6%	19.5%	9.6%
Adj EPS ⓘ	28.9%	31.1%	26.8%	14.5%
BVPSⓘ	79.7%	NA	46.5%	71.1%
Share Price	-	-	-	-17.2%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	45.6	35.3	2.2	7.3	357.5	163.1	33.2	26.1	26	19.8	14
Op. Profit Mgn % ⓘ	15.3	14.9	6.1	7.6	22.3	23.9	17.2	17.2	19.5	18.8	17.6
Net Profit Mgn % ⓘ	9.6	8.3	0.6	1.9	12.2	18.6	10.7	10.3	12.5	14.1	11.4
Debt to Equity ⓘ	0.2	0.6	0.6	0.5	-4.1	0.1	0	0.4	0.3	0	0
Working Cap Days ⓘ	140	133	154	127	123	110	92	101	114	111	135
Cash Conv. Cycle ⓘ	37	27	41	31	34	59	62	70	73	71	95

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	344	472	475	553	643	966	1,665	2,306	2,590	2,839
Operating Expenses ⓘ +	291	402	447	511	499	736	1,378	1,910	2,084	2,305
Manufacturing Costs	44	47	36	46	57	119	214	201	168	172
Material Costs	0	0	0	0	0	0	0	0	0	0
Employee Cost	183	268	317	367	370	536	1,014	1,465	1,652	1,815
Other Costs ⓘ	64	87	94	98	72	81	149	245	265	318
Operating Profit ⓘ	52	70	28	42	144	231	287	396	505	534
Operating Profit Margin (%)	15.3%	14.9%	5.9%	7.6%	22.3%	23.9%	17.2%	17.2%	19.5%	18.8%
Other Income ⓘ +	3	1	3	7	4	31	26	58	76	107
Exceptional Items ⓘ	0	0	0	0	-44	3	-47	0	2	0
Interest ⓘ	2	10	8	6	9	7	6	31	49	22
Depreciation ⓘ	15	19	12	17	19	26	33	60	76	80
Profit Before Tax ⓘ	38	42	11	26	75	231	226	363	459	539
Tax ⓘ	3	3	7	12	26	46	64	97	122	133
Profit After Tax	35	39	4	14	49	186	163	266	337	407
PAT Margin (%)	10.3%	8.3%	0.8%	2.6%	7.7%	19.2%	9.8%	11.5%	13.0%	14.3%
Adjusted EPS (₹)	1.8	2.0	0.2	0.7	-0.3	7.6	7.5	12.0	15.2	17.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	11.80%

Valuation of Indegene - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	89	130	134	149	-109	320	758	1,046	1,398	2,580
Share Capital ⓘ	79	79	79	79	0	0	0	44	44	48
Reserves ⓘ	10	51	55	70	-110	320	758	1,002	1,353	2,532
Debt +	11	66	37	53	435	18	11	394	343	0
Long Term Debt	2	23	1	8	341	18	11	394	333	0
Short Term Debt	9	42	36	45	95	0	0	0	10	0
Minority Interest	0	0	0	0	89	9	0	0	0	0
Trade Payables	31	47	38	47	55	50	74	73	118	93
Others Liabilities ⓘ	59	68	99	78	92	163	441	623	616	563
Total Liabilities ⓘ	190	310	308	326	562	559	1,284	2,137	2,475	3,236
Fixed Assets
Net Fixed Assets ⓘ +	33	81	75	104	119	86	138	664	646	678
Gross Block	75	141	148	194	259	191	271	863	995	1,096
Accumulated Depreciation	41	60	74	90	140	105	134	199	349	418
CWIP ⓘ	4	9	24	0	0	0	0	0	0	4
Investments ⓘ	0	1	0	0	13	0	120	614	797	1,290
Inventories	0	0	0	0	0	0	0	0	0	0
Trade Receivables	73	105	111	90	175	285	444	642	648	751
Cash Equivalents	10	18	9	37	180	140	517	86	191	375
Others Assets ⓘ	69	96	88	95	73	48	66	131	194	139
Total Assets ⓘ	190	310	308	326	562	559	1,284	2,137	2,475	3,236

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	29	27	24	65	22	172	297	130	508	442
PBT ⓘ	38	42	11	26	15	196	226	363	459	539
Adjustment ⓘ	16	29	23	21	94	17	87	91	78	39
Changes in Working Capital ⓘ	-18	-26	-3	35	-59	9	54	-216	96	24
Tax Paid ⓘ	-8	-18	-7	-18	-27	-50	-70	-108	-125	-160
Cash Flow From Investing Activity ⓘ +	-17	-77	-21	-19	-19	-24	-160	-893	-327	-683
Capex	-17	-20	-21	-17	-6	-21	-25	-19	-11	-30
Net Investments	2	-56	0	0	-1	-5	-136	-881	-329	-701
Others ⓘ	-2	-0	-0	-2	-12	1	0	7	13	49
Cash Flow From Financing Activity ⓘ +	-18	57	-12	-21	136	-132	233	333	-66	288
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	263	0	0	733
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	-7	383	-61	-333
Interest Paid ⓘ	-2	-9	-8	-6	-4	-4	-3	-18	-32	-10
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-16	65	-4	-15	140	-128	-20	-33	26	-102
Net Cash Flow ⓘ	-6	7	-9	25	140	16	370	-430	114	47

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0	126.12	7.55	22.54	N/A	176.32	30.2	29.5	27.56	20.45
ROCE (%)	43.74	33.32	8.93	14.82	N/A	68.54	41.09	35.2	30.88	25.24
Asset Turnover Ratio	1.91	1.89	1.54	1.75	1.45	1.72	1.81	1.35	1.12	0.99
PAT to CFO Conversion(x)	0.83	0.69	6	4.64	0.45	0.92	1.82	0.49	1.51	1.09
Working Capital Days
Receivable Days	66.30	68.80	83.10	66.50	75.50	87	80	85.90	90.90	90
Inventory Days	0	0	0	0	0	0	0	0	0	0
Payable Days	0	0	0	0	0	0	0	0	0	0

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indegene Ltd FAQs

The current trading price of Indegene on 11-Jun-2026 15:07 is ₹505.4.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Jun-2026 the market cap of Indegene stood at ₹12,491.9 Cr

The latest P/E ratio of Indegene as of 10-Jun-2026 is 58.95.

The latest P/B ratio of Indegene as of 10-Jun-2026 is 6.00.

The 52-week high of Indegene is ₹620.0 and the 52-week low is ₹414.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Indegene is ₹1,221 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Indegene Ltd is a good quality company.

The key valuation ratios of Indegene Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Indegene Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Indegene Ltd

Indegene is a digital-first life sciences commercialization company, enabling biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and scale the impact of their products with greater speed, precision, and efficiency. As a specialized company, it combines healthcare domain expertise, fit-for-purpose technology, and an agile operating model to solve the most complex problems in the healthcare industry. The company’s integrated portfolio spans commercial, medical, regulatory, and R&D / Clinical operations of life sciences companies.

The company enjoys a differentiated positioning as a digital-first commercialization and transformation partner to the life sciences industry. This stems from a combination of strong attributes cultivated over the years - deep domain expertise, a technology-first mindset, trusted customer relationships, and an agile operating model. As the industry evolves, the company continues to bolster its strengths, infusing AI into its solutions and driving operational excellence to create sustained value for stakeholders.

Solutions and Business Models

Enterprise Commercial Solutions: It caters to the digital marketing operations of the life sciences companies, a significant cost item.
Omnichannel Activation: It augments the promotion of biopharmaceutical products and medical devices to HCPs for life sciences companies across channels.
Enterprise Medical Solutions: It aims to consolidate large-scale regulatory and medical operations for life sciences companies through its Centers of Excellence (CoEs), comprising multi-disciplinary teams that work on one or more client engagements.
Others: It also offers Enterprise Clinical Solutions and Consultancy Services.

Business area of the company

The company offers solutions straddling the different stages of the commercialization lifecycle of drugs and medical devices. It caters to the commercial function needs of life sciences companies through its Enterprise Commercial Solutions and its Omnichannel Activation Solutions. For the medical and R&D function needs, it operates through its Enterprise Medical Solutions and Enterprise Clinical Solutions.

Key Awards, accreditations and recognition

2016: Ranked 88th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2016: Received the Business World HR Excellence Award for ‘Best Implementation of HR Technology’.
2017: Ranked 86th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2017: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2017: Recognised as one of the ‘Healthy Workplaces in India’ by Arogya World.
2018: Ranked 60th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2018: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2019: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2019: Recognised as one of the ‘Platinum Healthy Workplaces in India’ by Arogya World India Trust.
2020: Ranked in the ‘Top 50’ category of ‘India’s Best Workplaces for Women’ by Great Place to Work, India.
2020: Ranked 96th among ‘India’s Best Companies to Work for’ by Great Place to Work, India.
2020: Recognised as one of the ‘100 Best Companies for Women in India’ by Working Mother Media and Avtar Group.
2020: Recognised as one of ‘India’s Best Workplaces in Health and Wellness’ by Great Place to Work, India.
2021: Ranked 100th among ‘India’s Best Companies to Work for’ by Great Place to Work, India and the Economic Times.
2021: Ranked in the ‘Top 100’ category of ‘India’s Best Workplaces for Women’ (large organisations) by Great Place to Work, India.
2021: Recognised as one of the ‘100 Best Companies for Women in India’ by Seramount (formerly Working Mother Media) and Avtar Group.
2021: Recognised as one of ‘India’s Best Workplaces in Health and Wellness’ by Great Place to Work, India.
2022: Ranked 438th among ‘Asia-Pacific High-Growth Companies’ by Financial Times.
2022: Recognised as a leader by Everest Group, in its ‘Life Sciences Commercial Services Specialists PEAK Matrix Assessment 2022’.
2022: Recognised for its ‘Commitment to being a Great Place to Work’ by Great Place to Work, India.
2022: Recognised as ‘India’s Best Workplaces in Health and Wellness’ by Great Place to Work, India.
2023: Recognised as one of ‘India’s Best Workplaces in Professional Services’ by Great Place to Work, India.
2023: Awarded under the ‘Data Engineering for Good’ category at the Data Engineering Awards, 2023 by Analytics India Magazine.
2023: Awarded the ‘Best Overall AI-based Analytics Solution’ at the AI Breakthrough Awards, 2023.
2023: Recognised as a life sciences specialist with deep domain pockets and outcomes to match by HFS Horizons in the Life Sciences Service Providers, 2023.
2023: Awarded the Platinum level by Arogya World at the Healthy Workplace Conference and Awards, 2023.
2023: Certified as a great workplace by Great Place to Work Institute, India.
2024: Recognised as a leader by Everest Group, in its ‘Life Sciences Digital Services Specialists PEAK Matrix Assessment 2024’.
2024: Certified as a great workplace by Great Place to Work Institute, India.

Major events and milestones

1998: Indegene founded.
2000: Introduced medical education services to Indian pharmaceutical companies Launched Indegene Mobile Health System (IMHS) for medical doctors to easily access licensed medical content via PalmPilots.
2001: Recognized by Lancet as the most credible source of specialized medical information in India.
2001: Selected by WHO as their partner to implement a nationwide healthcare information project.
2003: Made a successful entry into sales training through launch of e-learning platform in diabetes across S.E. Asia.
2004: Incorporated 100% subsidiaries in the United States and Singapore.
2005: Nadathur Investments invested in Indegene.
2005: Set up operations in the United States.
2005: Acquired Medsn, a pharma sales training company in the United States.
2006: Ramped up operations in Southeast Asia.
2006: Acquired MedCases, a medical e-learning solutions company in the United States.
2007: Kicked off operations in Europe.
2007: Received ISO 9001 and ISO 27001 certifications.
2007: Launched Medical Affairs services.
2010: Built China Operation Center at Shanghai and Dalian.
2011: Launched Analytics services.
2012: Introduced Regulatory Affairs and Safety services.
2012: Acquired Aptilon, a customer engagement technology company.
2013: Acquired Total Therapeutic Management (TTM), a healthcare quality improvement and clinician engagement company.
2015: Acquired SmartCare, a population health analytics platform.
2016: Acquired Skura Technologies to expand omnichannel and commercial solutions.
2016: Acquired Encima to strengthen omnichannel analytics capabilities.
2016: Introduced next-generation, fully integrated product commercialization solutions.
2016: Acquired Wincere to strengthen footprint in R&D and Medical offerings for life sciences.
2017: Introduced Clinical services.
2019: Acquired DT Associates, a digital transformation and customer experience consulting firm in the UK.
2019: Launched Indegene Digital Summit, a flagship thought leadership event.
2020: Set up operations in Japan.
2021: The Carlyle Group and Brighton Park Capital invested $200 million in Indegene.
2021: Indegene refreshed its brand to align with its purpose - To enable healthcare organizations be future-ready.
2021: Strengthened pricing, reimbursement and market access capabilities with MME acquisition.
2022: Acquired CultHealth, a full-service healthcare marketing agency to elevate brand experience.
2023: Opened strategic center in Germany.
2024: Set up a new global delivery center in Hyderabad.
2024: Acquired Trilogy Writing & Consulting GmbH, a medical writing consultancy.
2024: Indegene listed on NSE and BSE.
2025: Acquired MJL Life Sciences to expand healthcare communications in the UK.
2025: Launched a new entity in Spain.
2025: Opened a new center in London.

Indegene Ltd (INDGN)

Indegene Ltd (INDGN)

Indegene stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Indegene - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indegene Ltd FAQs

About Indegene Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Indegene Ltd (INDGN)

Indegene Ltd (INDGN)

Indegene stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Indegene - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indegene Ltd FAQs

What is the share price of Indegene?

What is the market cap of Indegene?

What is the P/E ratio of Indegene?

What is the P/B ratio of Indegene?

What is the 52-week high and low of Indegene?

What is the TTM revenue of Indegene?

Is Indegene Ltd a good quality company?

Is Indegene Ltd undervalued or overvalued?

Is Indegene Ltd a good buy now?

About Indegene Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.